| Business

Become a contributor

Bookmark Econotimes

| Business

JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026

DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing

Italy Fines Apple €98.6 Million Over App Store Dominance

Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies

John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training

South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge

Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling

BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands

Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance

Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions

Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing

Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss

FDA Approves Mitapivat for Anemia in Thalassemia Patients

Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector

Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions

Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares

Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy

©Econometrics LLC . All Rights Reserved.

Vical Provides Company Update at BIO CEO and Investor Conference

Tuesday, February 7, 2017 11:30 AM UTC

SAN DIEGO, Feb. 07, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 1:00 p.m. EST on Tuesday, February 14, at the Biotechnology Innovation Organization (BIO) CEO and Investor Conference (New York – February 13-14). A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact: 
Tony Ramos
(858) 646-1127
Website: www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Palau Agrees to Accept Up to 75 U.S.-Transferred Migrants in Deal Tied to Increased American Aid

Christmas Eve Jazz Concert Canceled After Kennedy Center Renaming to Include Trump

BOJ Governor Signals Gradual Rate Hikes as Japan’s Inflation Nears 2% Target

U.S. Prioritizes Economic Pressure With Venezuelan Oil Quarantine as Sanctions Intensify

Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains

Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy

Democratic Governors Urge Trump Administration to Lift Halt on East Coast Offshore Wind Projects

U.S. Shifts Strategy Toward Economic Pressure With Venezuelan Oil Quarantine

Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical Provides Company Update at BIO CEO and Investor Conference

Editor's Picks

Welcome to EconoTimes